A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.
In a first-ever pilot study, called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.
“This is the first prospective study in our field to compare outcomes between different ways to achieve cardiac resynchronization,” said cardiologist Roderick Tung, MD, FHRS, the Director of Cardiac Electrophysiology & EP Laboratories at the University of Chicago Medicine. “Through His bundle pacing, we’re trying to tap into the normal wiring of the heart and restore conduction the way nature intended. Previously, we have just accepted that we had to bypass it through pacing two ventricles at a time.”
Tung spearheaded the two-year trial with UChicago Medicine cardiologist Gaurav Upadhyay, MD, FHRS, lead author of the study. The trial involved 40 adult patients across seven institutions in the Midwest. The UChicago Medicine team served as the independent coordinating site. Results of the study were presented as a featured late-breaking trial at the Heart Rhythm Society’s annual scientific sessions in San Francisco on May 9. To qualify as a late-breaking trial, the research must be groundbreaking and unique. The study was also published in the Journal of the American College of Cardiology.
A different resynchronization method
Biventricular pacing involves implanting wires, called leads, to simultaneously pace the right and left ventricles of the heart. A pacemaker then sends a timed electric pulse to the two leads with the goal of a synchronized contraction, which closely simulates the heart’s natural heartbeat.
Nevertheless, roughly 30 percent of patients do not respond to biventricular pacing treatment, which has been shown to improve survival in clinical trials.
Tung’s team looked to see if another resynchronization method could help reduce that number by doing a clinical trial comparison between biventricular pacing and His bundle pacing. The latter involves implanting a single lead at the start of the heart’s wiring system, which then naturally branches in two to organically distribute the pacemaker’s electric pulse to both ventricles.
“Permanent His bundle pacing has been around for almost 20 years, but until now there hasn’t been randomized clinical trials on how it compares to biventricular pacing,” Tung said.
For the His SYNC trial, all of the patients met the current guidelines for receiving cardiac resynchronization therapy and were randomly selected to receive either a His bundle pacer or a coronary sinus lead for biventricular pacing. Patients weren’t told which treatment they received.
While the results of the preliminary study did not demonstrate superiority with His-CRT, Tung and his team believe a His bundle pacing approach showed comparable rates of response, warranting further study. The research was limited by a high crossover rate, which was required by the study’s protocol if an adequate lead placement could not be achieved. Nearly half of the patients selected to receive His bundle pacing had to eventually be treated with traditional biventricular pacing due to having a condition called interventricular conduction delay (IVCD). The implantation tools have also not been refined since their introduction 10 years ago.
“We need to learn how to better identify patients who cannot and will not respond to His bundle pacing,” Tung said. “During this pilot study, we learned that the net was cast too wide, and patients with IVCD can’t be corrected and improved by His bundle pacing. His SYNC II, our planned follow-up study, will specifically exclude these patients and this is perhaps the most valuable lesson from the pilot, in addition to estimated treatment effect size.”
In addition, 26 percent of patients chosen to receive biventricular pacing did not, usually because a lead could not be inserted due to the condition of their veins dictated by strict criteria to optimize implantation of left ventricular leads.
Comparing the two approaches
After six months, researchers compared the electrical synchronization and structural function of the two patient groups’ hearts. Although they expected His bundle pacing to be superior, they found no overall significant differences in the two groups, with comparable rates of electrical resynchronization and echocardiographic response.
After one year, there were no differences in the number of hospitalizations or deaths.
Noting the pilot study was limited by its size, Tung says the results indicate further investigation is needed.
“Pilot studies are never meant to be conclusive,” he said. “They’re meant to inform us about effect size, safety and feasibility to help select appropriate patients and power larger studies.”
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Firefighters who responded to World Trade Center attacks more likely to have heart diseaseon September 6, 2019 at 2:00 pm
The first firefighters on the scene of the 9/11 terrorist attacks in New York City have an increased risk of heart disease, according to a new study. Arriving when the airborne dust was thickest at ...
- Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemyon September 6, 2019 at 12:06 pm
After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE:BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene (NASDAQ:CELG), a bidding war ...
- First Firefighters to Arrive at World Trade Center on 9/11 Have a Far Higher Risk of Heart Diseaseon September 6, 2019 at 9:01 am
A study of almost 10,000 firefighters who worked at the World Trade Center on September 11 has found those exposed to the dust which emerged from the destroyed buildings were more likely to develop ...
- Despite Heart Failure, This Man Maintains His Active Lifestyleon September 6, 2019 at 5:07 am
Today’s Fitness Friday episode includes an interview with David Van Deusen, who will talk with us about staying active despite living with heart disease. He has a fascinating story to tell our Not Old ...
- Will DAPA-HF Turn the Tide on Heart Failure?on September 6, 2019 at 4:43 am
Crucially, DAPA-HF was a heart failure trial; more than half the patients did not have diabetes. Journalist Patrice Wendling has excellent coverage of the trial: Here are some key points from the ...
- Occlutech AFR Heart Failure Device Obtains CE Mark Approvalon September 6, 2019 at 3:12 am
SCHAFFHAUSEN, Switzerland, Sept. 6, 2019 /PRNewswire/ -- Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales ...
- Being vegetarian or vegan could 'lower heart disease risk but increase chance of stroke'on September 5, 2019 at 7:51 am
People who follow vegan and vegetarian diets have a lower risk of heart disease, but a higher risk of stroke, new research suggests. A study, by the University of Oxford, found 20% higher rates of ...
- Vegetarian diet linked with 22 per cent lower risk of heart diseaseon September 4, 2019 at 3:42 pm
Eating a vegetarian diet rather than consuming meat has been linked with a significantly lower risk of coronary heart disease. While the environmental case for going vegetarian is unequivocal and ...
- Vegetarian and pescetarian diets linked to lower risk of coronary heart diseaseon September 4, 2019 at 3:32 pm
Vegetarian (including vegan) and pescetarian diets may be linked to a lower risk of coronary heart disease, or CHD for short, than diets that include meat, suggest the findings of a large UK study ...
- Vegetarian, Vegan Diets Linked to Lower Heart Disease Risk, but Higher Risk of Strokeon September 4, 2019 at 3:30 pm
Vegetarian and pescetarian diets could lower the risk of coronary heart disease, according to research. But vegetarians and vegans are also more likely to have strokes than meat eaters. The study ...
via Bing News